Posts tagged as: CTIX stock quote back to homepage
 |
Dosing Underway with Cellceutix’s New Cancer Drug at Dana-Farber(0) Cellceutix Hits Major Milestone in Company History; Dosing Underway for New Cancer Drug at Leading Hospitals Kevetrin is First-in-Class of Novel Chemistry to Reach Clinical Stage Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, is pleased to report that dosing of patients is now being conducted in clinical trials with Kevetrin(TM), the Company’s novel anti-cancer drug candidate, at Harvard University’s Dana Farber Cancer Center and Beth Israel Deaconess Medical Center. Read More |
 |
Cellceutix Clinical Trials at Dana Farber and Beth Israel Deaconess Now Active(0) The day of dosing cancer patients with Kevetrin is drawing near according to news this morning from Cellceutix Corporation (OTCBB: CTIX). The Beverly, Massachusetts-based company said today that clinical trials for their novel anti-cancer drug have gone active at Harvard’s Dana-Farber Cancer Center and partner Beth Israel Deaconess Medical Center. Dosing should begin within Read More |
|
Cellceutix Cancer Drug Expanding to Three Different Clinical Trials(0) There is starting to be a steady buzz across the web about Cellceutix Corporation (OTCBB: CTIX) and its novel cancer drug, Kevetrin™. For starters, the p53-activating drug is on tap to begin dosing patients with solid tumors any day now in clinical trials at the vaunted Harvard University’s Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center. Second, Cellceutix has reported that Beth Israel Read More |
 |
Cellceutix Selects Dr. Reddy’s for Manufacturing of New Psoriasis Drug(0) Beverly, Massachusetts-based Cellceutix Corporation (OTCBB: CTIX) reported this morning that they have chosen Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) to synthesize and manufacture Prurisol, Cellceutix’s lead anti-psoriasis drug candidate. Cellceutix will be advancing Prurisol into Phase II/III clinical trials under guidance from the Food and Drug Administration that the drug qualifies for a 505(b)(2) designation. Read More |
 |
Cellceutix on Seeking Alpha: Pfizer Eyes Kevetrin?(0) An article from August 13 by Seeking Alpha contributor A. Jackson discussed the state of big pharma’s pipelines and the potential of Cellceutix (OTCBB: CTIX) anti-cancer drug, Kevetrin, as it enters clinical trials at Dana-Farber and Beth Israel Deaconess. More acutely, Jackson details the relationship between Pfizer and Cellceutix and why the smaller biotech could be a logical acquisition target for the world’s biggest drug maker. Read More |
 |
FDA Gives Nod to Cellceutix for 505(b)(2) Eligibility for Psoriasis Drug(0) Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, reports today that it has participated in a meeting with the U.S. Food and Drug Administration (“FDA”) pertaining to the Company’s psoriasis compound, Prurisol™. As previously disclosed on April 16, 2012, the Company had Read More |
|
Cellceutix CEO and Advisor Jim Boeheim Interviewed by Boston Herald About New Cancer Drug(0) Company Provides Update on p53 Compounds From Annual ASCO Meeting Cellceutix Corporation (CTIX) (the “Company”), a biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers, is pleased to report that its Chief Executive Officer, Leo Ehrlich, and Cellceutix advisor Jim Boeheim, Read More |
|
Cellceutix Files Amended IND for Novel p53 Anti-Cancer Drug(0) The countdown has begun for Cellceutix to begin testing their lead compound, anti-cancer drug Kevetrin, at Dana-Farber and Beth Israel Deaconess. After a mild setback with Formatech going bankrupt, the company has completed the necessary changes to the Investigational New Drug application related to Quality Control testing and stability studies through a new supplier and added the data to the IND. This is great news for biotech traders and Cellceutix faithful as investors are eager to see the new drug in humans because Read More |
|
Cellceutix Secures $1 Million; Clinical Trials on Tap for Cancer Drug(0) Mass High Tech ran the story last Thursday after Cellceutix Corporation (OTCBB: CTIX) submitted a regulatory filing with the Security and Exchange Commission related to securing the funds, but this morning the company released press discussing their securing of $1 million in financing for their planned clinical trials on Kevetrin™, their flagship anti-cancer drug. The trials are slated to be held at Harvard’s Dana-Farber Cancer Institute. Read More |
 |
FDA to Expedite the Drug Approval Process for Breakthroughs(0) An article released yesterday by Reuters titled, “U.S. may speed approval of ‘breakthrough’ drugs” could prove extremely valuable for biotechs of all sizes. According to the article,
|
OTCBB News
read more
Stay Informed
Dana-Farber to Host Cellceutix Trials
Diabetes Rate Growing Exponentially
According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.
